AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12145069 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Bupivacaine
Number of subjects: 60
Study 12145069 — intervention group
Group type: COMPARATOR
Intervention: 0.1% Ropivacaine and 0.1% Bupivacaine
Number of subjects: 60
Study 9950311 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% sucrose
Number of subjects: 102
Study 9950311 — intervention group
Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 102
Study 9950311 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 102
Study 7768250 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-300 mg sustained release diltiazem (200-300 SR) administered once daily
Number of subjects: 144
Study 7768250 — intervention group
Group type: COMPARATOR
Intervention: Standard diltiazem (D) given three or four times daily
Number of subjects: 144
Study 2100165 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupranolol 0.25% in an oily solution
Number of subjects: 0
Study 6259250 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6
Study 6259250 — intervention group
Group type: COMPARATOR
Intervention: Control (no propranolol)
Number of subjects: 6
Study 30389476 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity morning training (Mm)
Number of subjects: 14
Study 30389476 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning training (Me)
Number of subjects: 14
Study 30389476 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning training
Number of subjects: 14
Study 30389476 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous training (Vm)
Number of subjects: 14
Study 30389476 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous training (Ve)
Number of subjects: 14
Study 27600367 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 666
Study 27600367 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 666
Study 27600367 — intervention group
Group type: COMPARATOR
Intervention: Placebo (withdrawal)
Number of subjects: 666
Study 27600367 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib re-treatment (5 mg and 10 mg)
Number of subjects: 666
Study 24880907 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group 1 (n = 66) received 125 ml of ONS twice per day, at 12 and 17 o'clock
Number of subjects: 234
Study 24880907 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group 2 (n = 80) received 62 ml of ONS four times a day, at 8, 12, 17 and 20 o'clock
Number of subjects: 234
Study 24880907 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (n = 88) offered ONS 125 ml twice per day in between meals
Number of subjects: 234
Study 23247302 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg twice daily
Number of subjects: 88
Study 23247302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 21069516 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg sustained release)
Number of subjects: 11
Study 21069516 — intervention group
Group type: EXPERIMENTAL
Intervention: Light treatment (0700 to 0800 hours)
Number of subjects: 11
Study 21069516 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg sustained release) plus Light treatment
Number of subjects: 11
Study 21069516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 19164853 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (1Hz) to the premotor cortex (PMC) for five consecutive days
Number of subjects: 6
Study 19164853 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 6
Study 19164853 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy controls received one real rTMS session
Number of subjects: 6
Study 17213754 — intervention group
Group type: EXPERIMENTAL
Intervention: ERr 731 (1 enteric coated tablet daily for 12 weeks)
Number of subjects: 109
Study 17213754 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet daily for 12 weeks)
Number of subjects: 109
Study 17213754 — intervention group
Group type: EXPERIMENTAL
Intervention: ERr 731
Number of subjects: 109
Study 15489491 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced low vision rehabilitation model (ELVR)
Number of subjects: 226
Study 15489491 — intervention group
Group type: COMPARATOR
Intervention: Conventional low vision rehabilitation (CLVR)
Number of subjects: 226
Study 12402283 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing (QST)
Number of subjects: 22
Study 12402283 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve conduction studies
Number of subjects: 22
Study 12402283 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic skin responses
Number of subjects: 22
Study 12402283 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration thresholds
Number of subjects: 22
Study 10052571 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion sickness and headache/migraine occurrence during the race
Number of subjects: 0
Study 10052571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical pattern of motion sickness and headache related to menstrual cycle
Number of subjects: 0
Study 10052571 — intervention group
Group type: COMPARATOR
Intervention: Comparison of male and female subjects
Number of subjects: 0
Study 7973552 — intervention group
Group type: EXPERIMENTAL
Intervention: Open wound healing technique
Number of subjects: 1208
Study 7973552 — intervention group
Group type: COMPARATOR
Intervention: Semi-closed wound healing technique
Number of subjects: 1208
Study 2502048 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral Parenteral Nutrition (PPN)
Number of subjects: 0
Study 2502048 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 900915 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor 250 mg orally
Number of subjects: 0
Study 900915 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin 250 mg orally
Number of subjects: 0
Study 31431372 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepitel® Film (MEP)
Number of subjects: 28
Study 31431372 — intervention group
Group type: COMPARATOR
Intervention: Standard care (STD)
Number of subjects: 28
Study 28635368 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stromal/stem cells
Number of subjects: 3
Study 28635368 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondrocytes
Number of subjects: 3
Study 28635368 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined autologous stromal/stem cells and chondrocytes
Number of subjects: 3
Study 28635368 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 3
Study 1375713 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with collagen sponge implant containing 100 micrograms of antimetabolite (5‐fluorouracil or bleomycin)
Number of subjects: 15
Study 1375713 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 15
Study 1375713 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil
Number of subjects: 15
Study 22325668 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone health coaching (intervention group)
Number of subjects: 64835
Study 22325668 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 64835
Study 20432351 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 43
Study 20432351 — intervention group
Group type: EXPERIMENTAL
Intervention: C-PET
Number of subjects: 43
Study 20432351 — intervention group
Group type: COMPARATOR
Intervention: FDG-PET
Number of subjects: 43
Study 18713920 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg nicotine patch
Number of subjects: 90
Study 18713920 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 90
Study 15918297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with a monomeric allergoid of Cupressus arizonica pollen
Number of subjects: 20
Study 15918297 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 12917171 — intervention group
Group type: EXPERIMENTAL
Intervention: OBF pneumotonometry
Number of subjects: 10
Study 12917171 — intervention group
Group type: COMPARATOR
Intervention: Goldmann tonometry
Number of subjects: 10
Study 10507957 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted-dose warfarin (6 trials, 2900 participants)
Number of subjects: 9874
Study 10507957 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (6 trials, 3119 participants)
Number of subjects: 9874
Study 10507957 — intervention group
Group type: COMPARATOR
Intervention: Adjusted-dose warfarin (5 trials, 2837 participants)
Number of subjects: 9874
Study 8734888 — intervention group
Group type: EXPERIMENTAL
Intervention: Braced ankle
Number of subjects: 12
Study 8734888 — intervention group
Group type: COMPARATOR
Intervention: Bare ankle under static conditions
Number of subjects: 12
Study 8734888 — intervention group
Group type: COMPARATOR
Intervention: Bare ankle under dynamic conditions
Number of subjects: 12
Study 2010876 — intervention group
Group type: EXPERIMENTAL
Intervention: Information condition (provided information summarizing the psychosocial sequelae of child survivors of cancer)
Number of subjects: 168
Study 2010876 — intervention group
Group type: COMPARATOR
Intervention: No information condition (not provided information summarizing the psychosocial sequelae of child survivors of cancer)
Number of subjects: 168
Study 6352850 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits by physicians
Number of subjects: 0
Study 30961342 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate prevention group
Number of subjects: 56
Study 30961342 — intervention group
Group type: COMPARATOR
Intervention: Caffeine citrate treatment group
Number of subjects: 56
Study 30508196 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily
Number of subjects: 120
Study 30508196 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib 250 mg once daily
Number of subjects: 120
Study 28478132 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib 100 mg
Number of subjects: 307
Study 28478132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study 26908810 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valganciclovir
Number of subjects: 0
Study 26908810 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir
Number of subjects: 0
Study 24389240 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar drink
Number of subjects: 185
Study 24389240 — intervention group
Group type: COMPARATOR
Intervention: Non-caloric sweetener drink
Number of subjects: 185
Study 22264885 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% fluorometholone 3 times a day (steroid group)
Number of subjects: 42
Study 22264885 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of steroid eye drops (no steroid group)
Number of subjects: 42
Study 22264885 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 19429734 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence-satisfaction with taking medication
Number of subjects: 253
Study 19429734 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence-satisfaction with testing blood glucose
Number of subjects: 253
Study 19429734 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief that type 2 diabetes is a serious problem
Number of subjects: 253
Study 19429734 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 253
Study 19429734 — intervention group
Group type: EXPERIMENTAL
Intervention: Being married
Number of subjects: 253
Study 19429734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost as a barrier to self-care behaviors
Number of subjects: 253
Study 18257436 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 19
Study 18257436 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 19
Study 18257436 — intervention group
Group type: COMPARATOR
Intervention: Manipulative therapy
Number of subjects: 19
Study 18257436 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 19
Study 18257436 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 19
Study 18257436 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant ultrasound therapy
Number of subjects: 19
Study 18257436 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs, exercise therapy, manipulative therapy, corticosteroid injection, acupuncture
Number of subjects: 19
Study 16697494 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil (3g/day for 2 months)
Number of subjects: 10
Study 15477632 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin
Number of subjects: 448
Study 15477632 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 448
Study 11168226 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 mixture of autogenous bone particles and bioactive glass particles (BG-particles)
Number of subjects: 10
Study 11168226 — intervention group
Group type: COMPARATOR
Intervention: Bone particles only (control side)
Number of subjects: 10
Study 11168226 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sides (experimental and control)
Number of subjects: 10
Study 8970755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 62
Study 8970755 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin‐clavulanate
Number of subjects: 62
Study 1451219 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml of glucose-free lidocaine 2%
Number of subjects: 50
Study 1451219 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 ml of glucose-free lidocaine 2%
Number of subjects: 50
Study 1451219 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml of glucose-free lidocaine 2%
Number of subjects: 50
Study 3881598 — intervention group
Group type: COMPARATOR
Intervention: 10-day treatment
Number of subjects: 44
Study 3881598 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-day treatment
Number of subjects: 44
Study 31805855 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum block (QLB) with 0.25% bupivacaine, repeated bilateral QLB for postoperative analgesia.
Number of subjects: 62
Study 31805855 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural analgesia with 6 ml/h of 0.25% bupivacaine during surgery and 6 ml/h of 0.125% bupivacaine for 24 h post-surgery.
Number of subjects: 62
Study 31805855 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum block (QLB) with 0.25% bupivacaine.
Number of subjects: 62
Study 31805855 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural analgesia.
Number of subjects: 62
Study 31805855 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum block (QLB).
Number of subjects: 62
Study 31805855 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum block (QLB) and continuous epidural analgesia.
Number of subjects: 62
Study 28089476 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMA levels (0.9±0.2μmol/L)
Number of subjects: 1276
Study 28089476 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest ADMA quintile (≥1.07μmol/L)
Number of subjects: 1276
Study 28089476 — intervention group
Group type: EXPERIMENTAL
Intervention: SDMA levels (4.3±1.4μmol/L)
Number of subjects: 1276
Study 26149722 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily SMS messages (direct, PIN-protected, coded) and transportation reimbursements (about $6 USD) for participants returning within seven days.
Number of subjects: 183
Study 26149722 — intervention group
Group type: COMPARATOR
Intervention: Control group (pre-intervention period) with no SMS messages or transportation reimbursements.
Number of subjects: 183
Study 24047438 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin (AZT) 1000 mg orally
Number of subjects: 83
Study 24047438 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZT) 500 mg daily for 9 and 14 days
Number of subjects: 83
Study 24047438 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (DOX) 200 mg for 21 days
Number of subjects: 83
Study 24047438 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study 20819978 — intervention group
Group type: COMPARATOR
Intervention: Psilocybin (0.2 mg/kg)
Number of subjects: 12
Study 19789402 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Number of subjects: 152
Study 19789402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 17944893 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal hospital diet plus 400‐mL oral nutritional supplements daily for 6 weeks
Number of subjects: 225
Study 17944893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 15547534 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter balloon inflated with 80 mL of sterile saline
Number of subjects: 203
Study 15547534 — intervention group
Group type: COMPARATOR
Intervention: Foley catheter balloon inflated with 30 mL of sterile saline
Number of subjects: 203
Study 11675190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleural tenting
Number of subjects: 20
Study 11675190 — intervention group
Group type: COMPARATOR
Intervention: No pleural tenting (Control)
Number of subjects: 20
Study 9154856 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest wall vibration (CW) during hypercapnia
Number of subjects: 10
Study 9154856 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest wall vibration (CW) during exercise
Number of subjects: 10
Study 9154856 — intervention group
Group type: COMPARATOR
Intervention: Deltoid vibration (DV) during hypercapnia
Number of subjects: 10
Study 9154856 — intervention group
Group type: COMPARATOR
Intervention: No vibration (NV) during hypercapnia
Number of subjects: 10
Study 9154856 — intervention group
Group type: COMPARATOR
Intervention: Deltoid vibration (DV) during exercise
Number of subjects: 10
Study 9154856 — intervention group
Group type: COMPARATOR
Intervention: No vibration (NV) during exercise
Number of subjects: 10
Study 7696154 — intervention group
Group type: EXPERIMENTAL
Intervention: Image analysis of DNA ploidy in colorectal carcinoma specimens
Number of subjects: 19
Study 3305744 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality approach in rectal carcinoma patients (stages B2 and C)
Number of subjects: 0
Study 31239591 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric Lavage (GL)
Number of subjects: 0
Study 29234747 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless implant placement
Number of subjects: 92
Study 29234747 — intervention group
Group type: COMPARATOR
Intervention: Flap implant placement
Number of subjects: 92
Study 26712786 — intervention group
Group type: EXPERIMENTAL
Intervention: MT10107
Number of subjects: 25
Study 26712786 — intervention group
Group type: COMPARATOR
Intervention: onabotulinumtoxinA
Number of subjects: 25
Study 23426035 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent lifestyle intervention (reduced‐energy, low‐glycemic load, high‐fiber diet with behavioral change education)
Number of subjects: 133
Study 23426035 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent lifestyle intervention
Number of subjects: 133
Study 23426035 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured weight‐maintenance program
Number of subjects: 133
Study 23426035 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention worksites (not enrolled in weight‐loss program)
Number of subjects: 133
Study 21296838 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time audio and visual feedback during CPR
Number of subjects: 1586
Study 21296838 — intervention group
Group type: COMPARATOR
Intervention: No feedback during CPR
Number of subjects: 1586
Study 19673983 — intervention group
Group type: EXPERIMENTAL
Intervention: Biophage-PA (therapeutic bacteriophage preparation)
Number of subjects: 24
Study 19673983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19673983 — intervention group
Group type: EXPERIMENTAL
Intervention: Biophage-PA
Number of subjects: 24
Study 16495395 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride 50 mg three times daily
Number of subjects: 554
Study 16495395 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride 100 mg three times daily
Number of subjects: 554
Study 16495395 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride 200 mg three times daily
Number of subjects: 554
Study 16495395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554
Study 16495395 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride (combined doses)
Number of subjects: 554
Study 16495395 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride (100 mg and 200 mg)
Number of subjects: 554
Study 15100202 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass (OPCAB)
Number of subjects: 200
Study 15100202 — intervention group
Group type: COMPARATOR
Intervention: Conventional coronary artery bypass grafting (CABG) with cardiopulmonary bypass
Number of subjects: 200
Study 14616590 — intervention group
Group type: EXPERIMENTAL
Intervention: AM149 1% (new formulation of propofol)
Number of subjects: 30
Study 14616590 — intervention group
Group type: COMPARATOR
Intervention: Disoprivan 1% (standard formulation of propofol)
Number of subjects: 30
Study 10808691 — intervention group
Group type: EXPERIMENTAL
Intervention: Chula Mental Test (CMT)
Number of subjects: 48
Study 10808691 — intervention group
Group type: EXPERIMENTAL
Intervention: Clock-Drawing Test (CDT)
Number of subjects: 48
Study 10808691 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous application of CDT and CMT
Number of subjects: 48
Study 8989072 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored exercise training
Number of subjects: 51
Study 8989072 — intervention group
Group type: EXPERIMENTAL
Intervention: Coached exercise training
Number of subjects: 51
Study 1637794 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat/cholesterol supplement (31 g fat, 650 mg cholesterol)
Number of subjects: 51
Study 1637794 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat/cholesterol supplement
Number of subjects: 51
Study 1637794 — intervention group
Group type: COMPARATOR
Intervention: Fat-free supplement
Number of subjects: 51